This journal article is a practice guideline that provides recommendations summarizing the growing literature and current best practices of chronic Hepatitis C Virus (HCV) treatment, including treatment in difficult-to-treat populations. These recommendations are based on an extensive review of published data, national consensus recommendations, and input from thought leaders involved in HCV care and treatment.
This information sheet presents facts about viral hepatitis in tabular format. It discusses hepatitis A, B, and C. It lists statistics; routes of transmission; persons at risk; incubation period; symptoms of acute infection; the likelihood of symptomatic acute infection; the potential for chronic infection; the severity; serologic tests for acute and chronic infection; screening recommendations for chronic infection; treatment; vaccination recommendations and schedule, if any; and testing recommendations.
This pamphlet discusses hepatitis C virus infection (HCV) for the newly-diagnosed patient. It explains the disease including acute and chronic infection, its symptoms, effect on the liver, treatment including the two oral medications cleared by the Federal Drug Administration for patients with hepatitis C genotype 1, preventing transmission to others, treatment outcomes and complications of chronic HCV, and the outlook for people with chronic HCV. It includes a list of questions for the patient to ask his/her healthcare provider and a list of resources.
This report describes approaches for managing patients with TB who are candidates for or who are undergoing protease inhibitor therapy and presents interim recommendations for managing these patients until additional data are available and formal guidelines are issued. Protease inhibitors interact with rifamycin derivatives, which are used to treat and prevent the mycobacterial infections commonly observed in patients with the HIV. The report provides background information on the management of TB and the three treatment options currently available for these patients.
This report provides information about opportunistic infections (OIs) among persons with HIV. It discusses the causes, effects, and treatments available and includes a comparison of costs of treatment and prophylaxis for the most common OIs. It provides recommendations to improve healthcare and prevent OIs among HIV-positive persons.
This report discusses the hepatitis C virus (HCV), how it is treated, and how it can be prevented. The report examines the epidemiology of HCV. It discusses the screening tests, history, general treatment, and postexposure prophylaxis for HCV. The report explains the ways that HCV can be transmitted from person to person and how the virus can be spread through bodily fluid. It identifies the most serious high risk behaviors such as injection drug use and certain sexual practices. The report cites the risks associated with health care work.
Because TB treatment is inextricably involved in a host of psychological, social, and economic problems, this manual was developed to help providers establish and enhance social support services in a TB clinic. The purpose of the manual is to help the worker establish social services, develop a therapeutic alliance with clients, create an intake form to identify barriers to TB treatment and formulate goals to reduce those barriers and to increase client functioning, counsel and help clients achieve their goals, form support groups, and lead or participate in case management.
This report provides preliminary information about 21 cases of liver injury associated with a two-month rifampin-pyrazinamide (RIF-PZA) regimen for the treatment of latent TB infection (LTBI). The report also includes the revised recommendations on selecting appropriate LTBI therapy for patients and monitoring the use of RIF-PZA to treat LTBI. Of the 21 patients with RIF-PZA liver injury, 16 recovered and five died of liver failure. In most instances, the nine-month isoniazid regimen is preferred for the treatmemt of patients with LTBI.
This report updates previous US Public Health Service recommendations for the management of health-care personnel (HCP) who have occupational exposure to blood and other body fluids that may contain Hepatitis B, Hepatitis C, or HIV/AIDS. It contains recommendations for Hepatitis B Virus postexposure management including initiation of hepatitis B vaccine series to any susceptible, unvaccinated person who sustains blood or body fluid exposure. Guidance is provided to clinicians and exposed HCP for selecting the appropriate HBV postexposure prophylaxis (PEP).
This comprehensive plan for health care professionals and policy makers addresses the prevention and control of hepatitis C virus (HCV) infection and its consequences. This strategy strives to protect the public's health by outlining guidelines for prevention and control of HCV infection, providing credible information on hepatitis C to enhance healthy decisions and promoting healthy living through strong partnerships with national, state, and local organizations in both the public and private sectors.